AKT1 and diffuse large B-cell lymphoma: Ibrutinib, when combined with bortezomib, also presented a synergism by enhancing apoptosis in DLBCL and MCL cells through AKT and NFκB inactivation [60], while in DLBCL it showed cumulative antitumor effects with other agents, such as enzastaurin [61] or lenalidomide [62].